Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-5,181
Closed -$1.19M 318
2024
Q4
$1.19M Sell
5,181
-1,198
-19% -$288K 0.36% 71
2024
Q3
$1.56M Buy
6,379
+1,728
+37% +$386K 0.28% 73
2024
Q2
$890K Buy
4,651
+3,669
+374% +$744K 0.14% 96
2024
Q1
$194K Buy
982
+167
+20% +$30.6K 0.02% 239
2023
Q4
$140K Buy
815
+393
+93% +$60.4K 0.01% 265
2023
Q3
$62K Sell
422
-408
-49% -$73.8K 0.01% 312
2023
Q2
$181K Hold
830
0.01% 257
2023
Q1
$182K Buy
830
+154
+23% +$33.4K 0.01% 235
2022
Q4
$141K Hold
676
0.01% 233
2022
Q3
$148K Hold
676
0.01% 235
2022
Q2
$142K Hold
676
0.01% 271
2022
Q1
$164K Buy
676
+254
+60% +$61.4K 0.01% 254
2021
Q4
$110K Hold
422
﹤0.01% 255
2021
Q3
$111K Sell
422
-140
-25% -$38.3K ﹤0.01% 253
2021
Q2
$139K Hold
562
0.01% 222
2021
Q1
$109K Hold
562
﹤0.01% 243
2020
Q4
$119K Buy
562
+113
+25% +$22.5K 0.01% 228
2020
Q3
$77K Buy
+449
New +$82.9K ﹤0.01% 248
2019
Q4
Sell
-15,295
Closed -$2.07M 128
2019
Q3
$2.07M Sell
15,295
-30,762
-67% -$4.03M 0.13% 81
2019
Q2
$5.62M Sell
46,057
-8,454
-16% -$936K 0.31% 67
2019
Q1
$5.67M Buy
+54,511
New +$5.63M 0.29% 73
2017
Q2
Sell
-58,612
Closed -$4.22M 141
2017
Q1
$4.22M Sell
58,612
-68,176
-54% -$4.71M 0.16% 84
2016
Q4
$7.87M Sell
126,788
-253,543
-67% -$15.5M 0.32% 68
2016
Q3
$24.6M Sell
380,331
-492,950
-56% -$32.8M 0.89% 46
2016
Q2
$55.2M Sell
873,281
-311,999
-26% -$18.4M 2.21% 14
2016
Q1
$68.5M Buy
1,185,280
+114,759
+11% +$6.5M 2.7% 7
2015
Q4
$57.5M Sell
1,070,521
-33,071
-3% -$1.86M 2.48% 10
2015
Q3
$56.2M Buy
1,103,592
+424,373
+62% +$22.8M 2.2% 17
2015
Q2
$38.3M Buy
+679,219
New +$42.9M 1.4% 29

Other funds holding RMD

TOBAM's RMD Position: Q1 2025 in Review

TOBAM sold out of ResMed (RMD) in Q1 2025, closing a stake of 5,181 shares — an estimated $1.19M sold.

TOBAM first reported a position in RMD in Q2 2015 and held it in 29 quarters. The position peaked at $68.5M in Q1 2016. 885 funds tracked by Wall St. Rank hold RMD as of Q1 2025.

  • TOBAM reported no remaining ResMed position as of Q1 2025 after selling out during the quarter.
  • TOBAM sold 5,181 ResMed shares in Q1 2025, an estimated $1.19M.
  • TOBAM first reported a position in ResMed in Q2 2015 and held it in 29 quarters.
  • TOBAM's ResMed position peaked at $68.5M in Q1 2016.
  • 885 funds tracked by Wall St. Rank held ResMed as of Q1 2025.

Based on TOBAM's 13F filing for Q1 2025, filed 16 Apr 2025.